The Medicines and Healthcare products Regulatory Agency has issued a drug alert over an injection used to relieve acute migraines called.
Five batches of the Imigran product – either treatment or refill packs – have been recalled by GlaxoSmithKline due to a manufacturing fault causing a small number of needles to protrude from the protective shield.
MHRA Defective Medicines Recall Centre manager Adam Burgess said: “The number of needles affected is thought to be very small and the risk to members of the public finding an affected syringe is extremely low.
“There is, however, a slight risk of infection from an unprotected needle and we would ask people to take extra care when using these syringes.”
The MHRA drug alert identified the affected batch numbers as:
- Imigran Inj/ Subject Treatment – C640404, C638748, C636954
- Imigran Inj / Subject Treatment Refill – C639899, C638737